Novel compounds of the formula (I), in which W, T, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and X 7 have the meanings indicated in Patent Claim 1 , are suitable as antidiabetics.
1. A compound selected from the following compounds A1 to A27:
No.
Structure and/or name
“A1”
2-{2-[3-(2,6-Dimethylphenylamino)imidazo[1,2-a]pyrimidin-
2-yl]phenoxy}acetamide
“A2”
2-{2-[3-(2,6-Dimethylphenylamino)-5,7-dimethylimidazo-
[1,2-a]pyrimidin-2-yl]phenoxy}acetamide
“A3”
(2,6-Dichlorophenyl)-{2-[2,4-dimethoxy-6-(5-methylamino-
1,3,4-oxadiazol-2-yl)phenyl]imidazo[1,2-a]pyrimidin-3-yl}-
amine
“A4”
(2,6-Dichloro-4-fluorophenyl)-{2-[2,4-dimethoxy-6-(5-
methylamino-1,3,4-oxadiazol-2-yl)phenyl]imidazo[1,2-a]-
pyrimidin-3-yl}amine
“A5”
(2,6-Dichlorophenyl)-{2-[2-(5-ethylamino-1,3,4-oxadiazol-2-
yl)-4,6-dimethoxyphenyl]imidazo[1,2-a]pyrimidin-3-yl}amine
“A6”
5-{2-[3-(2,6-Dichlorophenylamino)imidazo[1,2-a]pyrimidin-
2-yl]-3,5-dimethoxyphenyl}-3H-1,3,4-oxadiazol-2-one
“A7”
2-{2-[3-(2,6-Dichlorophenylamino)imidazo[1,2-a]pyrimidin-
2-yl]-3-ethylphenoxy}acetamide
“A8”
2-{2-[3-(2,6-Dimethylphenylamino)imidazo[1,2-a]pyrimidin-
2-yl]-3-ethylphenoxy}acetamide
“A9”
2-{2-[3-(2,6-Dimethylphenylamino)imidazo[1,2-a]pyrimidin-
2-yl]-3-ethyl-5-methoxyphenoxy}acetamide
“A10”
2-{2-[3-(2,6-Dimethylphenylamino)imidazo[1,2-a]pyrimidin-
2-yl]-5-methoxy-3-methylphenoxy}acetamide
“A11”
{2-[2,4-Dimethoxy-6-(5-methylamino-1,3,4-oxadiazol-2-yl)-
phenyl]imidazo[1,2-a]pyrimidin-3-yl}-(2,6-dimethylphenyl)-
amine
“A12”
2-{2-[3-(2,6-Dichlorophenylamino)imidazo[1,2-a]pyrimidin-
2-yl]-3-ethyl-5-methoxyphenoxy}acetamide
“A13”
(2,6-Dichloro-4-fluorophenyl)-{2-[2-(5-methylamino-1,3,4-
oxadiazol-2-yl)phenyl]imidazo[1,2-a]pyrimidin-3-yl}amine
“A14”
(2,6-Dichlorophenyl)-{2-[2-(5-methylamino-1,3,4-oxadiazol-
2-yl)phenyl]imidazo[1,2-a]pyrimidin-3-yl}amine
“A15”
(2,6-Dichlorophenyl)-{2-[2-(5-ethylamino-1,3,4-oxadiazol-2-
yl)phenyl]imidazo[1,2-a]pyrimidin-3-yl}amine
“A16”
{2-[2,4-Dichloro-6-(5-methylamino-1,3,4-oxadiazol-2-yl)-
phenyl]imidazo[1,2-a]pyrimidin-3-yl}-(2,6-dimethylphenyl)-
amine
“A17”
2-[3-(2,6-Dichlorophenylamino)imidazo[1,2-a]pyrimidin-2-
yl]-3,5,N-trimethoxybenzamide
“A18”
2-[3-(2,6-Dichlorophenylamino)imidazo[1,2-a]pyrimidin-2-
yl]-3,5-dimethoxybenzohydrazide
“A19”
{2-[2-Chloro-6-(5-methylamino-1,3,4-oxadiazol-2-yl)phenyl]-
imidazo[1,2-a]pyrimidin-3-yl}-(2,6-dimethylphenyl)amine
“A20”
Methyl 3-chloro-2-[3-(2,6-dimethylphenylamino)imidazo-
[1,2-a]pyrimidin-2-yl]benzoate
“A21”
(2,6-Dimethylphenyl)-{2-[4-methoxy-2-(5-methylamino-
1,3,4-oxadiazol-2-yl)phenyl]imidazo[1,2-a]pyrimidin-3-yl}-
amine
“A22”
{2-[2-Chloro-6-(5-methylamino-1,3,4-oxadiazol-2-yl)phenyl]-
imidazo[1,2-a]pyrimidin-3-yl}-(2-chloro-6-methylphenyl)-
amine
“A23”
(2,6-Dichloro-3-methylphenyl)-{2-[2,4-dimethoxy-6-(5-
methylamino-1,3,4-oxadiazol-2-yl)phenyl]imidazo[1,2-a]-
pyrimidin-3-yl}amine
“A24”
2-[3-(2,6-Dichloro-3-methylphenylamino)imidazo[1,2-a]-
pyrimidin-2-yl]-N-ethyl-3,5-dimethoxybenzamide
“A25”
(3,5-Dimethylisoxazol-4-yl)-{2-[2-(5-methylamino-1,3,4-
oxadiazol-2-yl)phenyl]imidazo[1,2-a]pyrimidin-3-yl}amine
“A26”
(2-Chloro-6-methylphenyl)-{2-[2-fluoro-6-(5-methylamino-
1,3,4-oxadiazol-2-yl)phenyl]imidazo[1,2-a]pyrimidin-3-yl}-
amine
“A27”
(4-Fluoro-2,6-dimethylphenyl)-{2-[2-fluoro-6-(5-methyl-
amino-1,3,4-oxadiazol-2-yl)phenyl]imidazo[1,2-a]pyrimidin-
3-yl}amine
or a pharmaceutically usable salt or stereoisomer thereof, including mixtures thereof in all ratios.
2. A medicament composition comprising at least one compound according to claim 1 or a pharmaceutically usable salt or stereoisomer mixture thereof in all ratios, and optionally excipients and/or adjuvants.
3. A method for treating a patient suffering from type 1 or type 2 diabetes comprising administering to said patient a compound according to claim 1 or a pharmaceutically usable salt or stereoisomer thereof.
4. A method of lowering blood sugar in a patient comprising administering to said patient a compound according to claim 1 or a pharmaceutically usable salt or stereoisomer thereof.